Boston University
Characterization of human adenosine monophosphate deaminase regulation and structural guided inhibitor design of human ketohexokinase as therapeutic targets of fructose-related diseases
Abstract
dc:description.abstractLiver human adenosine 5’-monophosphate deaminase (hAMPD2) and human ketohexokinase C (hKHK-C) were studied as drug targets for individuals with fructose related diseases, such as hereditary fructose intolerance (HFI) or non-alcoholic fatty liver diseases (NAFLD). hAMPD2 is a two-domain zinc metalloenzyme involved in the purine degradation pathway and catalyzes the deamination of adenosine 5’-monophosphate (AMP) into inosine 5’-monophosphate (IMP) and ammonia. It is regulated by several cytoplasmic molecules, adenosine 5’-triphosphate (ATP), an activator, guanosine 5’-triphosphate (GTP) and inorganic phosphate (Pi), both inhibitors, with the small N-terminal domain hypothesized as being regulatory based on the sequence divergence between each isoform of hAMPD. Under fructose consumption, the purine degradation and de novo biosynthesis pathways are activated, leading to an increase in concentration of the final product, uric acid, which causes mitochondrial dysfunction and the development of gout.In vitro characterization of hAMPD2 under physiological and high fructose intake conditions provide a proposed link between hAMPD2 regulation and fructose consumption. In this work, I show that the small N-terminal domain of hAMPD2 does not have a regulatory role, and hAMPD2 is physiologically inactivated through GTP and Pi inhibition. Upon fructose ingestion, hepatic concentrations of all three regulators of hAMPD2 decrease, resulting in enzyme activation through ATP binding, leading to increase concentration of uric acid. A panel of different compounds was screened in vitro against hAMPD2 to determine potential de novo inhibitors targeting hAMPD2 to block the uric acid pathway in patients with fructose-related diseases. hKHK-C is the first enzyme in the fructose catabolic pathway. It phosphorylates fructose into fructose 1-phosphate (Fru 1-P), which is then catabolized by aldolase B. In addition, resulting adenosine 5’-diphosphates (ADPs) are catalyzed into ATP and AMP, and AMP enters the pathway described above which ultimately leads to uric acid. In HFI patients, catabolism of Fru 1-P is prevented due to non-functional aldolase B, resulting in Fru 1-P accumulating and liver toxicity. To prevent this, hKHK-C was used as a drug target for individuals with HFI. In this work, I determined several structures of inhibitor-bound KHK-C for structural guided inhibitor studies using X-ray crystallography. Analysis of these structures revealed two key interactions in the ATP binding pocket with the compounds: one with R108 of one molecule of the functional hKHK-C dimer, and the other with D27 of the other molecule of the dimer, which correlate with an increase in potency.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Chemistry
- Grantor
- Boston University
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Rebelo, Ashley Marie-Alice
- Advisor dc:contributor.advisor
-
- Allen, Karen N.
- ORCID dc:identifier.orcid
Subjects
dc:subject × 5Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53313